doi: 10.1161/hc4401.098429
(Circulation. 2001;104:2453.)
© 2001 American Heart Association, Inc.
Basic Science Reports |
Cyclooxygenase-1 and -2 Knockout Mice Demonstrate Increased Cardiac Ischemia/Reperfusion Injury but Are Protected by Acute Preconditioning
From the NIEHS, NIH, Research Triangle Park (M.G.W.C., S.A.G., P.C., J.A.B., R.L., D.C.Z., E.M.), and Division of Pediatric Cardiology, Duke University Medical Center, Durham (M.G.W.C.), NC.
Correspondence to Darryl C. Zeldin, MD, NIEHS, MD D2-01, Research Triangle Park, NC 27709. E-mail zeldin{at}niehs.nih.gov
Background— The purpose of this study was to examine the effects of cyclooxygenase (COX) deficiency on baseline functional characteristics and on recovery of left ventricular developed pressure (LVDP) after 20 minutes of global ischemia and 40 minutes of reperfusion in untreated and preconditioned hearts.
Methods and Results— Compared with hearts from wild-type (WT) and COX-2-/- mice, baseline cardiac prostaglandin (PG) E2 and 6-keto-PGF1
levels were significantly decreased in hearts from COX-1-/- mice. After ischemia, cardiac PGE2 levels increased in WT, COX-1-/-, and COX-2-/- mice (P<0.05). Recovery of function (LVDP) after global ischemia in hearts from COX-1-/- and COX-2-/- mice was significantly less than in WT hearts. Pretreatment of WT mice with indomethacin for 2 days before ischemia significantly decreased LVDP recovery; however, perfusion of WT hearts with indomethacin for 40 minutes before ischemia did not significantly alter LVDP recovery. Postischemic recovery of LVDP in COX-1-/- and COX-2-/- was unchanged by perfusion with 5 µmol/L PGE2, PGD2, PGF2, or carboprostacyclin. Hearts from COX-2-/- mice showed an increase in ischemic contracture compared with hearts from WT and COX-1-/- mice; however, hearts did not differ in intracellular pH, ATP, or inorganic phosphate during ischemia. Ischemic preconditioning significantly improved postischemic LVDP recovery in COX-1-/-, COX-2-/-, and WT mice.
Conclusions— Genetic disruption or 2-day chemical inhibition of COX-1 and COX-2 decreases recovery of LVDP after ischemia; however, acute perfusion with indomethacin is not detrimental. These data are consistent with protection due to the altered expression of some protein that is modulated by COX or its metabolites.
Key Words: ischemia • reperfusion • preconditioning • prostaglandin • cyclooxygenase
This article has been cited by other articles:
 |
|
 |
|
  N. Y. Tan and L. M. Khachigian Sp1 Phosphorylation and Its Regulation of Gene Transcription Mol. Cell. Biol., May 15, 2009; 29(10): 2483 - 2488. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nacci, M. Tarquinio, L. De Benedictis, A. Mauro, A. Zigrino, M. R. Carratu, M. J. Quon, and M. Montagnani Endothelial Dysfunction in Mice with Streptozotocin-induced Type 1 Diabetes Is Opposed by Compensatory Overexpression of Cyclooxygenase-2 in the Vasculature Endocrinology, February 1, 2009; 150(2): 849 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Kellogg, K. Converso, T. Wiggin, M. Stevens, and R. Pop-Busui Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H453 - H461. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sun, E. Sheveleva, B. Xu, H. Inoue, T. G. Bowden, and Q. M. Chen Corticosteroids induce COX-2 expression in cardiomyocytes: role of glucocorticoid receptor and C/EBP-{beta} Am J Physiol Cell Physiol, October 1, 2008; 295(4): C915 - C922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Frias, S. Somers, C. Gerber-Wicht, L. H. Opie, S. Lecour, and U. Lang The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis Cardiovasc Res, October 1, 2008; 80(1): 69 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Degousee, S. Fazel, D. Angoulvant, E. Stefanski, S.-C. Pawelzik, M. Korotkova, S. Arab, P. Liu, T. F. Lindsay, S. Zhuo, et al. Microsomal Prostaglandin E2 Synthase-1 Deletion Leads to Adverse Left Ventricular Remodeling After Myocardial Infarction Circulation, April 1, 2008; 117(13): 1701 - 1710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Li, Y. Guo, W. Tan, Q. Ou, W.-J. Wu, D. Sturza, B. Dawn, G. Hunt, C. Cui, and R. Bolli Cardioprotection Afforded by Inducible Nitric Oxide Synthase Gene Therapy Is Mediated by Cyclooxygenase-2 via a Nuclear Factor-{kappa}B Dependent Pathway Circulation, October 2, 2007; 116(14): 1577 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Birkenmeier, A. Staudt, W.-H. Schunck, I. Janke, C. Labitzke, T. Prange, C. Trimpert, T. Krieg, M. Landsberger, V. Stangl, et al. COX-2-dependent and potentially cardioprotective effects of negative inotropic substances released after ischemia Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2148 - H2154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Hopkins, N. Ouchi, R. Shibata, and K. Walsh Adiponectin actions in the cardiovascular system Cardiovasc Res, April 1, 2007; 74(1): 11 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Timmers, J. P.G. Sluijter, C. W.J. Verlaan, P. Steendijk, M. J. Cramer, M. Emons, C. Strijder, P. F. Grundeman, S. K. Sze, L. Hua, et al. Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the Pig Circulation, January 23, 2007; 115(3): 326 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lee, B. Kosaras, H. Aleyasin, J. A. Han, D. S. Park, R. R. Ratan, N. W. Kowall, R. J. Ferrante, S. W. Lee, and H. Ryu Role of cyclooxygenase-2 induction by transcription factor Sp1 and Sp3 in neuronal oxidative and DNA damage response FASEB J, November 1, 2006; 20(13): 2375 - 2377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X Liu, Z Zhou, X Feng, Z Jia, Y Jin, and J Xu Cyclooxygenase-2 plays an essential part in cardioprotection of delayed phase of recombinant human erythropoietin preconditioning in rats. Postgrad. Med. J., September 1, 2006; 82(971): 588 - 593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Neilan, G. A. Doherty, G. Chen, C. Deflandre, H. McAllister, R. K. Butler, S. E. McClelland, E. Kay, L. R. Ballou, and D. J. Fitzgerald Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H532 - H536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Neilan, D. S. Jassal, M. F. Scully, G. Chen, C. Deflandre, H. McAllister, E. Kay, S. C. Austin, E. F. Halpern, J. H. Harmey, et al. Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression Eur. Heart J., May 2, 2006; 27(10): 1251 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Gross, J. R. Falck, E. R. Gross, M. Isbell, J. Moore, and K. Nithipatikom Cytochrome P450 and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisited Cardiovasc Res, October 1, 2005; 68(1): 18 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Baber, W. Deng, J. Rodriguez, R. G. Master, T. J. Bivalacqua, A. L. Hyman, and P. J. Kadowitz Vasoactive prostanoids are generated from arachidonic acid by COX-1 and COX-2 in the mouse Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1476 - H1487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Jiang, E. Shi, Y. Nakajima, S. Sato, K. Ohno, and H. Yue Cyclooxygenase-1 Mediates the Final Stage of Morphine-Induced Delayed Cardioprotection in Concert With Cyclooxygenase-2 J. Am. Coll. Cardiol., May 17, 2005; 45(10): 1707 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shinmura, K. Tamaki, T. Sato, H. Ishida, and R. Bolli Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2093 - H2101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhatnagar Beating Ischemia: A New Feat of EETs? Circ. Res., September 3, 2004; 95(5): 443 - 445. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Baber, A. L. Hyman, and P. J. Kadowitz Role of COX-1 and -2 in prostanoid generation and modulation of angiotensin II responses Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2399 - H2410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bolli and K. Shinmura Cyclooxygenase-2 in myocardial ischemia: is it really a friend? Reply J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1714 - 1715. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. YELLON and J. M. DOWNEY Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology Physiol Rev, October 1, 2003; 83(4): 1113 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Murakami, K. Nakashima, D. Kamei, S. Masuda, Y. Ishikawa, T. Ishii, Y. Ohmiya, K. Watanabe, and I. Kudo Cellular Prostaglandin E2 Production by Membrane-bound Prostaglandin E Synthase-2 via Both Cyclooxygenases-1 and -2 J. Biol. Chem., September 26, 2003; 278(39): 37937 - 37947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Shinmura, M. Nagai, K. Tamaki, M. Tani, and R. Bolli COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2534 - H2543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bolli, K. Shinmura, X.-L. Tang, E. Kodani, Y.-T. Xuan, Y. Guo, and B. Dawn Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning Cardiovasc Res, August 15, 2002; 55(3): 506 - 519. [Abstract] [Full Text] [PDF]
|
|